

UCSF Medical Center

UCSF Adult Antimicrobial Stewardship Annual Overview and Utilization Report, FY18

Summary

Sarah Doernberg, MD, MAS
Alexandra Hiltz-Horeczko, PharmD
Lusha Wang, MPH
11.6.2018


Outline

- **Why?**
- Adult ASP Metrics FY18
 - Process measures
 - Outcome measures
 - Antibiotic use
 - Internal trends: APEX data
 - Benchmarking: Vizient data
 - Preliminary analysis of FY18 initiatives

Why stewardship?



23,000 annual AMR deaths



> 2 million AMR illnesses



MDRO incidence rate w/ ASP:
0.49 (0.35-0.68)




CDI incidence rate w/ ASP:
0.68 (0.53-0.88)

Outline


- Why?
- Adult ASP Metrics FY18
 - **Process measures**
 - Outcome measures
 - Antibiotic use
 - Internal trends: APEX data
 - Benchmarking: Vizient data
 - Preliminary analysis of FY18 initiatives

722 interventions made in FY18

Types of Recommendation (N=289)



Outcomes of Recommendation (N=289)





Outline

- Why?
- Adult ASP Metrics FY18
 - Process measures
 - **Outcome measures**
 - Antibiotic use
 - **Internal trends: APEX data**
 - Benchmarking: Vizient data
 - Preliminary analysis of FY18 initiatives

Days & length of therapy (DOT and LOT)

- Total number of days a patient receives any antibiotics



Data sources

- APEX

- UCSF EMR
- Data is based on medication administration
- Useful for granular look at trends within our hospital


- UHC/Vizient

- Consortium of hospitals
- Data is based on administrative claims
- Comparators chosen based on: perform BMT, kidney, liver, lung, AND heart transplants
- Most useful for benchmarking


Targeted antibiotics

- Aztreonam
- Cefepime
- Ceftaroline
- Ceftazidime
- Ceftazidime-avibactam
- Ceftolozane-tazobactam
- Daptomycin
- Doripenem
- Ertapenem
- Imipenem
- Linezolid
- Meropenem
- Piperacillin/tazobactam
- Tigecycline
- Vancomycin


UCSF Adult Antibiotic Utilization FY14-FY19 MTD




Targeted Antibiotics by Groups FY17 vs. FY18




Non-Targeted Antibiotics of Interest FY17 vs. FY18



Target Antibiotic Usage by Service FY17 vs. FY18




C. diff rate/10,000 patient days




Outline

- Why?
- Adult ASP Metrics FY18
 - Process measures
 - **Outcome measures**
 - Antibiotic use
 - Internal trends: APEX data
 - **Benchmarking: Vizient data**
 - Preliminary analysis of FY18 initiatives


UCSF & Comparators Targeted Antibiotic Usage




UCSF & Comparators Targeted Antibiotic Usage



UCSF & Comparators Targeted Antibiotic Usage




UCSF & Comparators Targeted Antibiotic Usage




Outline

- Why?
- Adult ASP Metrics FY18
 - Process measures
 - Outcome measures
 - Antibiotic use
 - Internal trends: APEX data
 - Benchmarking: Vizient data
 - **Preliminary analysis of FY18 initiatives**


Surgical prophylaxis compliance: Go-live 4/24/18



UA with reflex to UCx: Inpt Ucx rate



UA with reflex to UCx: Inpt UA rate



Summary

- We have sustained decreases seen in FY16 and 17 but progress has stalled
- Nice decrease in GNR agents
- Impact on CDI rates
- Will need to strategize to continue optimizing use
- Focus on high-utilizing services for next year
- Long-range: will need to incorporate outpatient, ED, and transitions of care

Thank you!

Questions: sarah.doernberg@ucsf.edu

UCSF Medical Center